{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:25:01Z","timestamp":1792689901770,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jaip.2021.09.050","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T02:40:26Z","timestamp":1634870426000},"page":"506-516.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug\u2013Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization"],"prefix":"10.1016","volume":"10","author":[{"given":"Tamara","family":"Quint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariga","family":"Ramazanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Arnoldner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Janik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Knerer-Schally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Griss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ristl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bangert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.09.050_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","article-title":"Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD","volume":"68","author":"Taniguchi","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2021.09.050_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","volume":"147","author":"Stevens","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)\u2014a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.09.050_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.iac.2016.06.005","article-title":"Pathogenesis of aspirin-induced reactions in aspirin-exacerbated respiratory disease","volume":"36","author":"Cahill","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.09.050_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaci.2011.09.019","article-title":"Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis","volume":"129","author":"Higashi","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jaci.2016.09.025","article-title":"Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease","volume":"139","author":"Cahill","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4168\/aair.2015.7.4.321","article-title":"Local immunoglobulin E in the nasal mucosa: clinical implications","volume":"7","author":"De Schryver","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2021.09.050_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/ajra.2014.28.4054","article-title":"Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease","volume":"28","author":"Johns","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2021.09.050_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovi\u0107","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.09.050_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.09.050_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib15","first-page":"8124","article-title":"Omalizumab treatment in Samter's triad: case series and review of the literature","volume":"23","author":"Cameli","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaip.2021.09.050_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2021.09.050_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaip.2016.12.013","article-title":"Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug\u2013exacerbated respiratory disease following treatment with omalizumab","volume":"5","author":"Phillips-Angles","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.09.050_bib18","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. a randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.09.050_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhino12.000","article-title":"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2021.09.050_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2021.09.050_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.09.050_bib23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2008.09.048","article-title":"Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease","volume":"123","author":"Hope","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib24","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jaci.2006.09.005","article-title":"Rhinosinusitis: developing guidance for clinical trials","volume":"118","author":"Meltzer","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/jcm9040925","article-title":"Associations between the quality of life and nasal polyp size in patients suffering from chronic rhinosinusitis without nasal polyps, with nasal polyps or aspirin-exacerbated respiratory disease","volume":"9","author":"Schneider","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaip.2021.09.050_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhn.2002.121022","article-title":"Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20)","volume":"126","author":"Piccirillo","year":"2002","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2021.09.050_bib27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s00106-007-1606-9","article-title":"Development of a grading scale for the Sino-Nasal Outcome Test-20 German Adapted Version (SNOT-20 GAV) [in German]","volume":"56","author":"Baumann","year":"2008","journal-title":"HNO"},{"key":"10.1016\/j.jaip.2021.09.050_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00106-005-1347-6","article-title":"Quality of life in patients with chronic rhinosinusitis: validation of the Sino-Nasal Outcome Test-20 German Adapted Version [in German]","volume":"55","author":"Baumann","year":"2007","journal-title":"HNO"},{"key":"10.1016\/j.jaip.2021.09.050_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe2749","article-title":"Persistence of mature dendritic cells, THA, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R\u03b1 blockade","volume":"6","author":"Bangert","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.09.050_bib31","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.21037\/jtd-20-2073","article-title":"Prediction of clinical response to omalizumab in moderate-to-severe asthma patients using the change in total serum IgE level","volume":"12","author":"Li","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jaip.2021.09.050_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anai.2020.08.008","article-title":"Aspirin desensitization vs biologics for patients with aspirin-exacerbated respiratory disease","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaci.2017.05.006","article-title":"Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single-center study","volume":"141","author":"Waldram","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaci.2013.07.004","article-title":"Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis","volume":"133","author":"Bochenek","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib35","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jaci.2004.07.013","article-title":"Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis","volume":"114","author":"Van Zele","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib36","first-page":"162","article-title":"An update on the impact of Staphylococcus aureus enterotoxins in chronic sinusitis with nasal polyposis","volume":"43","author":"Zhang","year":"2005","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2021.09.050_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.05.012","article-title":"Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma","volume":"130","author":"Bachert","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJM198110083051501","article-title":"The development of respiratory syncytial virus\u2013specific IgE and the release of histamine in nasopharyngeal secretions after infection","volume":"305","author":"Welliver","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2021.09.050_bib39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2332\/allergolint.11-RA-0403","article-title":"Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites","volume":"61","author":"Higashi","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2021.09.050_bib40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.02.005","article-title":"Accelerated dissociation of IgE-Fc\u03b5RI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cea.12668","article-title":"Comparable actions of omalizumab on mast cells and basophils","volume":"46","author":"Serrano-Candelas","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.09.050_bib43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","article-title":"Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma","volume":"124","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.09.050_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2021.09.050_bib46","doi-asserted-by":"crossref","first-page":"3254094","DOI":"10.1155\/2018\/3254094","article-title":"Omalizumab for severe asthma: beyond allergic asthma","volume":"2018","author":"Loureiro","year":"2018","journal-title":"Biomed Res Int"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821011326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821011326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:30:59Z","timestamp":1761975059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821011326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2213219821011326"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.09.050","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug\u2013Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.09.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}